Table 1 Summary of identified studies
First author | Year | Country | Study design | Multi/single centre | Number of metformin use in patients | Number of non-metformin use in patients | Female/male of metformin use in patients | Female/male of non-metformin use in patients | Mean age of metformin use in patients | Mean age of non-metformin use in patients | Study period | Primary Outcome | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Doenyas-Bara [19] | 2016 | Israel | RC | Single | 44 | 118 | 22/22 | 47/71 | 67 | 68 | 01/2011–06/2013 | In-hospital mortality | 0.42(0.27–0.66) | 0.21 (0.05–0.94) |
Green [21] | 2012 | America | RC | Single | 192 | 343 | NA | NA | 71 | 72 | 02/2007–10/2008 | 28-day mortality | NA | 0.38 (0.19–0.76) |
Jochmans [20] | 2017 | French | RC | Single | 52 | 79 | 19/33 | 23/56 | 74 | 68.4 | 10/2010–12/2013 | In-hospital mortality | 0.87 (0.43–1.78) | 0.61 (0.36–0.99) |
Park [22] | 2017 | Korea | RC | Single | 71 | 142 | 32/39 | 62/80 | 71 | 66 | 08/2008–09/2014 | 28-day mortality | 0.71 (0.32–1.58) | 1.09 (0.41–2.85) |
van Vught [23] | 2016 | Holland | OC | Multi | 114 | 127 | 36/78 | 61/66 | 67 | 65.1 | 01/2011–07/2013 | In-hospital mortality | 0.69 (0.40–1.19) | NA |